Featuring perspectives from Drs Justin Gainor, Corey Langer, Luis Paz‑Ares, Heather Wakelee, Jared Weiss and Helena Yu, including the following topics:
- Introduction (0:00)
- Incorporation of immunotherapeutic strategies into the management of nonmetastatic non-small cell lung cancer (NSCLC) — Heather Wakelee, MD (3:18)
- Contemporary treatment for localized and metastatic NSCLC with EGFR mutations — Helena Yu, MD (33:46)
- Research advances shaping the current and future treatment of metastatic NSCLC with ALK rearrangements, ROS1 rearrangements or RET fusions — Justin F Gainor, MD (58:03)
- Targeting alterations in MET, HER2, KRAS and other oncogenes in NSCLC — Jared Weiss, MD (1:19:24)
- Current and future management of metastatic NSCLC without a targetable tumor mutation — Corey J Langer, MD (1:42:57)
- Current treatment paradigm for small cell lung cancer — Luis Paz-Ares, MD, PhD (2:07:58)
CME information and select publications